TrueCAGR

Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARMBSE: 500420ISIN INE685A01028Face value ₹5standalone
₹4,699
+1.79% · 2026-11-20 · 52-wk ₹3,687–₹5,123
Source: BSE filings · Financials to FY2026 · 5 years of history · Data last updated: results filed 23 Oct 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
WatchTalking point

Cash conversion trending down

Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.

Importance 64 / 95 · cash quality

WatchTalking point

Profit lagging revenue

Revenue grew 21.4% but profit grew 11.9%, so the company kept less of each rupee of revenue as profit.

Revenue growth+21.4%Net profit growth+11.9%

Importance 64 / 95 · growth

StrengthTalking point

Compounding revenue

Revenue compounded at 13.2% a year over 4 years (₹8,508 → ₹13,980).

Importance 54 / 95 · growth

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.

Market cap
₹1.59 L cr
FY2026 revenue
₹10,712 cr
FY2026 net profit
₹2,192 cr
Net worth
₹8,452 cr
Total debt
₹14,164 cr
EPS (basic)
₹64.75
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 12 pharmaceuticals.

Section 04 · Business performance

Is the business growing?

Revenue grew 12.3% a year over 4 years, from ₹6,742 cr in FY2022 to ₹10,712 cr in FY2026. Net profit grew 22.0% a year over the same period.

Revenue & net profit — FY22 to FY26₹ crore · consolidated
₹'000 cr05101520023REVENUENET PROFIT7k991FY228k1,052FY239k1,357FY2410k1,888FY2511k2,192FY26
RevenueNet profit
Watch

Revenue grew 21.4% but profit grew 11.9%, so the company kept less of each rupee of revenue as profit.

Rule PROFIT_SLOWER_THAN_REVENUE

Revenue growth per year
+12.3%over 4 years (FY22–FY26)
Revenue growth
+10.6%vs last year
Net profit growth
+16.1%vs last year
Change in net profit since FY22
+121%

Revenue compounded at 13.2% a year over 4 years (₹8,508 → ₹13,980).

Over 4 years profit compounded at 28.8% a year while revenue compounded at 13.2% a year — though FY2023 saw a one-off step-change of 60% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Revenue grew 21.4% year on year (FY2025 → FY2026).

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,979 cr (up 50.8% on the same quarter last year) and net profit ₹534 cr (down 9.6%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Strength

Q2 FY27 revenue was ₹4,979 cr, up 50.8% from ₹3,302 cr in Q2 FY26 a year earlier.

Rule QTR_REVENUE_GROWTH_YOY

Strength

Q2 FY27 EBIT was ₹1,047 cr, up 22.9% from ₹852 cr a year earlier.

Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY

Watch

Q2 FY27 interest (finance cost) was ₹300 cr, up 525.0% from ₹48 cr a year earlier.

Rule QTR_INTEREST_EXPENSE_CHANGE_YOY

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr01345001REVENUENET PROFIT3k503Q3 '253k498Q4 '253k548Q1 '263k591Q2 '263k635Q3 '264k364Q4 '265k566Q1 '275k534Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY252,809+2.8%503+13.5%17.9%
Q4 FY252,959+7.8%498+10.9%16.8%
Q1 FY263,178+11.2%548+19.9%17.2%
Q2 FY263,302—591—17.9%
Q3 FY263,303+17.6%635+26.2%19.2%
Q4 FY264,197+41.8%364−26.9%8.7%
Q1 FY274,921+54.8%566+3.3%11.5%
Q2 FY274,979+50.8%534−9.6%10.7%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹17,400 crTTM
EBITDA
₹5,722 crTTM
EBIT
₹3,806 crTTM
PBT
₹2,813 crTTM
Net profit
₹2,099 crTTM

C. Corporate actions

29 May 2026DividendFinal Dividend - Rs. - 9.0000 — ₹9.00/share
18 Feb 2026DividendInterim Dividend - Rs. - 29.0000 — ₹29.00/share
20 Jun 2025DividendFinal Dividend - Rs. - 6.0000 — ₹6.00/share
31 Jan 2025DividendInterim Dividend - Rs. - 26.0000 — ₹26.00/share
21 Jun 2024DividendFinal Dividend - Rs. - 6.0000 — ₹6.00/share
12 Feb 2024DividendInterim Dividend - Rs. - 22.0000 — ₹22.00/share
23 Jun 2023DividendFinal Dividend - Rs. - 8.0000 — ₹8.00/share
3 Feb 2023DividendInterim Dividend - Rs. - 14.0000 — ₹14.00/share
8 Jul 2022Bonus issueBonus issue 1:1 — 1:2
3 Jun 2022DividendSpecial Dividend - Rs. - 15.0000 — ₹15.00/share
3 Jun 2022DividendFinal Dividend - Rs. - 8.0000 — ₹8.00/share
2 Feb 2022DividendInterim Dividend - Rs. - 25.0000 — ₹25.00/share
17 Jun 2021DividendFinal Dividend - Rs. - 15.0000 — ₹15.00/share
15 Feb 2021DividendInterim Dividend - Rs. - 20.0000 — ₹20.00/share
18 Mar 2020DividendInterim Dividend - Rs. - 17.0000 — ₹17.00/share
18 Mar 2020DividendSpecial Dividend - Rs. - 15.0000 — ₹15.00/share
13 Jun 2019DividendFinal Dividend - Rs. - 4.0000 — ₹4.00/share
6 Feb 2019DividendInterim Dividend - Rs. - 13.0000 — ₹13.00/share
18 Jun 2018DividendFinal Dividend - Rs. - 5.0000 — ₹5.00/share
15 Feb 2018DividendInterim Dividend - Rs. - 9.0000 — ₹9.00/share
19 Jun 2017DividendFinal Dividend - Rs. - 4.0000 — ₹4.00/share
10 Feb 2017DividendInterim Dividend - Rs. - 10.0000 — ₹10.00/share
16 Mar 2016DividendInterim Dividend - Rs. - 15.0000 — ₹15.00/share
11 Feb 2016DividendInterim Dividend - Rs. - 20.0000 — ₹20.00/share
15 Jun 2015DividendFinal Dividend - Rs. - 6.2500 — ₹6.25/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 38.0% in FY2026, against 34.2% in FY2022. ROE was 27.3% and ROCE 20.2% in FY2026.

Margins — FY22 to FY26% of revenue · consolidated
0%5%10%15%20%25%30%35%40%38.0%20.4%FY22FY23FY24FY25FY26
EBITDA marginNet margin
Concern

ROE declined from 26.5% to 17.0% year on year.

Rule ROE_DETERIORATED_YOY

EBITDA margin now
38.0%
5-year range
33.1–38.0%
ROE FY2026
27.3%
ROCE FY2026
20.2%
Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 1.68x in FY2026, against 0.53x in FY2022; interest coverage 9.70x. Operating cash flow was 1.25x net profit.

Net worth — FY22 to FY26₹ crore · consolidated
₹'000 cr03696kFY226kFY237kFY248kFY258kFY26
Net worth (shareholders' funds)
Watch

Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.

Rule CASH_CONVERSION_DETERIORATING

Operating cash flow vs net profit₹ crore · FY22–FY26
0k1k2k3k2k991FY222k1kFY233k1kFY243k2kFY253k2kFY26
Operating cash flowNet profit
Total debt
₹14,164 cr
Operating cash flow ÷ net profit
1.25×FY2026
Free cash flow
₹2,262 cr
Current ratio
1.07×

Net worth compounded at 31.1% a year over 4 years (₹5,953 → ₹17,585) — though FY2026 saw a one-off step-change of 132% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.41×).

Debt-to-equity rose from 0.40× to 0.84× year on year.

Free cash flow has been positive in 5 of the last 5 years.

Section 08 · Relative position

How does it compare with peers?

Within its 12-company Pharmaceuticals peer group, it ranks 4 of 12 on return on equity and 5 of 12 on EBITDA margin. Its P/E of 75.8 compares with a peer median of 45.3.

Ranked against 12 pharmaceuticals (FY2026, consolidated).

Revenue growth

TORNTPHARM · 4th of 12 · set median 14.8%

GLENMARK27.5%LUPIN23.1%LAURUSLABS22.7%TORNTPHARM21.4%MANKIND17.0%ZYDUSLIFE16.8%DIVISLAB12.8%SUNPHARMA11.2%BIOCON10.9%AUROPHARMA6.1%DRREDDY3.2%CIPLA2.2%

EBITDA margin

TORNTPHARM · 5th of 12 · set median 28.7%

DIVISLAB37.4%SUNPHARMA33.7%ZYDUSLIFE33.1%LUPIN33.1%TORNTPHARM31.9%GLENMARK29.6%MANKIND27.8%LAURUSLABS26.9%CIPLA24.0%DRREDDY23.2%BIOCON22.4%AUROPHARMA21.8%

Return on equity

TORNTPHARM · 4th of 12 · set median 14.4%

LUPIN26.9%ZYDUSLIFE18.3%LAURUSLABS17.7%TORNTPHARM17.0%DIVISLAB16.2%SUNPHARMA14.7%GLENMARK14.1%MANKIND12.5%CIPLA11.7%DRREDDY11.5%AUROPHARMA9.9%BIOCON1.1%

P/E ratio

TORNTPHARM · 9th of 12 · set median 45.3×

LUPIN17.6×AUROPHARMA26.2×ZYDUSLIFE28.1×CIPLA40.1×SUNPHARMA41.2×DRREDDY42.1×MANKIND48.5×GLENMARK51.5×TORNTPHARM75.8×DIVISLAB88.3×LAURUSLABS93.0×BIOCON174.3×
Context

Trades at 75.77× earnings — 67% above the pharmaceuticals median of 45.29×.

Rule PE_ABOVE_PEERS

P / E
75.8×TTM to Sept 26
P / B
9.0×latest book
P / S
9.1×TTM sales
Earnings yield
1.3%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 74.4× · P/S 11.4× · ROE 17.0%. TTM and full-year revenue and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.

Section 09 · The stock

How has the stock performed?

The share price is up 26.3% over 1 year, up 122% over 3 years (30.4% a year) and up 237% over 5 years (27.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 8.3% below its 52-week high.

Adjusted close — 2020-01 to 2026-11₹ per share · split / bonus adjusted
0k4k₹4,6992020202120222023202420252026
Context

Over 4 years profit (28.8% a year) and the stock (30.4% a year) compounded at roughly the same rate — but FY2022 profit (₹777) was well below the through-cycle level (~₹1,656), so this rate is inflated by the recovery from a low base.

Rule STOCK_TRACKED_EARNINGS · recovery

Business vs stock — 5-year compound annual rate
Net profit28.8%/yrShare price30.4%/yr
1-year return
+26.3%
3-year return
+121.7%
5-year return
+236.7%
From 52-wk high
−8.3%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Below₹4,739
vs 200-day avg
Above₹4,547
RSI (14)
51.4neutral
MACD histogram
5.0
From 52-wk high
−8.3%
From 52-wk low
+27.5%
30-day volatility
17.6%ann.
6-month return
+6.7%
RSI (14) · 0–10051.4 — neutral
0305070100OVERSOLDOVERBOUGHT51.4
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Cash conversion trending down
    Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.
    CASH_CONVERSION_DETERIORATING · conviction 64
  • Watch
    Profit lagging revenue
    Revenue grew 21.4% but profit grew 11.9%, so the company kept less of each rupee of revenue as profit.
    PROFIT_SLOWER_THAN_REVENUE · conviction 64
  • Concern
    Returns declining
    ROE declined from 26.5% to 17.0% year on year.
    ROE_DETERIORATED_YOY · conviction 52
  • Watch
    Receivables stretching
    Receivable days rose from 59 to 79 — collections are slower.
    RECEIVABLE_DAYS_JUMP · conviction 50
  • Concern
    Leverage rising
    Debt-to-equity rose from 0.40× to 0.84× year on year.
    LEVERAGE_INCREASED_YOY · conviction 48
Data coverage is complete — 5 years of financials (FY2022–FY2026), full P&L, balance sheet and cash-flow statement, sector metrics fully mapped.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY22FY23FY24FY25FY26
Revenue6,7427,6958,5339,68210,712
Total income6,9467,7778,6249,71410,730
EBITDA2,3042,5472,9813,6074,072
Profit before tax1,4661,5771,9172,6102,897
Net profit9911,0521,3571,8882,192
EPS (₹)58.631.140.155.864.8
Net worth6,3466,4566,8297,5928,452
Total debt3,3444,5663,3332,54714,164
Operating cash flow2,1402,2662,8932,5742,731
Free cash flow2,0351,8502,5812,1462,262
Key ratios — consolidated
RatioFY22FY23FY24FY25FY26
Growth
Revenue growth YoY—14.110.913.510.6
Profit growth YoY—6.229.039.116.1
Profitability
EBITDA margin %34.233.134.937.338.0
Net margin %14.313.515.719.420.4
Return on equity %15.616.420.426.227.3
Return on capital %17.618.121.028.020.2
Leverage & cash
Debt to equity0.530.710.490.341.68
Cash flow ÷ profit2.162.152.131.361.25
Current ratio1.621.151.251.461.07
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.